Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
Domenica Lorusso, Yang Xiang(Peking Union Medical College Hospital), Kosei Hasegawa(Saitama International Medical Center), Giovanni Scambia(Istituti di Ricovero e Cura a Carattere Scientifico), Manuel Leiva(Institute of Peruvian Studies), Pier Ramos-Elías(Liga Nacional Contra el Cáncer), Alejandro Acevedo, Jakub Cvek(University of Ostrava), Leslie M. Randall(Virginia Commonwealth University), Andrea Juliana Gomes(Liga Contra el Cancer), Fernando Contreras Mejía(Instituto Nacional de Cancerología), Limor Helpman(Tel Aviv University), Hüseyin Akıllı(Turkish Society of Cardiology), Jung‐Yun Lee(Severance Hospital), Valeriya Saevets(Chelyabinsk Regional Clinical Oncology Center), Flora Zagouri(Alexandra Hospital), Lucy Gilbert(McGill University Health Centre), Jalid Sehouli, Ekkasit Tharavichitkul(Chiang Mai University), Kristina Lindemann, Nicoletta Colombo, Chih‐Long Chang(Mackay Memorial Hospital), Markéta Bednaříková(Masaryk University), Hong Zhu(Xiangya Hospital Central South University), Ana Oaknin(Vall d'Hebron Institute of Oncology), Melissa Christiaens(KU Leuven), Edgar Petru, Tomoka Usami(Ehime Medical Center), Peng Liu(Merck & Co., Inc., Rahway, NJ, USA (United States)), Karin Yamada(Merck & Co., Inc., Rahway, NJ, USA (United States)), Sarper Toker(Merck & Co., Inc., Rahway, NJ, USA (United States)), Stephen J. O’Keefe(Merck & Co., Inc., Rahway, NJ, USA (United States)), Sandro Pignata(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Linda Duska(University of Virginia)
Cited by 149
Abstract
Related Papers
No related papers found
Powered by citation graph analysis